Nifty Growth Sectors 15 News and Updates

Keep track of all breaking news on Nifty Growth Sectors 15 from all sources in a single place.

Load latest

Sun Pharmaceutical Industries Ltd.

13 Apr 2025

1666.70

-0.99%

Stock downfall: The side effects are real, but Sun Pharma stays on its feet

Business Standard

Growth hormone kicks in as India's largest pharma firm's vital signs hold amid generic strain

Sun Pharmaceutical I.. has an average target of 2056.50 from 8 brokers.

Hero MotoCorp Ltd.

13 Apr 2025

4340.00

0.04%

Hero Motocorp leads two-wheeler sales, ends year with 29% market share

Business Line

Overall automobile retail sales in India rose 6% to 2,61,43,943 units in FY25 with rural areas performing better than urban regions across passenger vehicle and two-wheeler segments

Number of FII/FPI investors decreased from 1080 to 1011 in Mar 2025 qtr

Hero MotoCorp retains top spot in two-wheeler market with 29% market share

Business Standard | 13 Apr 2025

Hindustan Unilever Ltd.

13 Apr 2025

2369.20

-0.46%

5 of top 10 valued firms add Rs 84,559 crore in valuation last week; HUL major gainer

Economic Times

The market valuation of Hindustan Unilever surged Rs 28,700.26 crore to Rs 5,56,054.27 crore. Reliance Industries added Rs 19,757.27 crore, taking its market capitalisation (mcap) to Rs 16,50,002.23 crore.

Geojit BNP Paribas decreased Buy price target of Hindustan Unilever Ltd. to 2640.0 on 08 May, 2025.

5 top valued firms add 84,559 cr in valuation last week; HUL major gainer

Business Standard | 13 Apr 2025

Sun Pharmaceutical Industries Ltd.

13 Apr 2025

1666.70

-0.99%

Drug makers Glenmark, Sun Pharma, Zydus recall products in US

Business Line

Companies initiate Class-II recall, which happens when use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences

Motilal Oswal increased Buy price target of Sun Pharmaceutical Industries Ltd. to 2000.0 on 23 May, 2025.

Glenmark, Sun Pharma, Zydus Recall Products In US

NDTV Profit | 13 Apr 2025

Sun Pharmaceutical Industries Ltd.

11 Apr 2025

1666.70

-0.99%

Sun Pharma stock up 2.4% as roads cleared for launch of alopecia drug

Business Standard

According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma's sales in FY26, and $125 million in FY27

Sun Pharmaceutical Industries Ltd. is trading below all available SMAs

Here's why Sun Pharma share price advanced 5% in trade on April 11; details

Business Standard | 11 Apr 2025

Apollo Hospitals Enterprise Ltd.

11 Apr 2025

6976.00

-1.38%

Apollo Hospitals Planning Buyouts To Boost North India Footprint

NDTV Profit

Apollo will add about 3,500 beds over three to four years, with focus mainly on India's northern region.

Number of FII/FPI investors increased from 1501 to 1548 in Mar 2025 qtr.

Infosys Ltd.

11 Apr 2025

1572.90

0.18%

Infosys extends strategic partnership with AIB for digital banking transformation; sharesup by 1.46% on NSE

Business Line

The renewed agreement will see Infosys leverage its expertise in agile practices and AI-powered tools to help AIB enhance operational efficiency and expedite innovation across its banking platforms

Infosys Ltd. is trading below its 100 day SMA of 1689.3

Cipla Ltd.

11 Apr 2025

1469.60

-0.74%

Cipla gets USFDA nod to market generic version of cancer drug Abraxane

Business Standard

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for paclitaxel protein-bound particles for injectable suspension (albumin-bound), 100 mg/vial, single-dose vial, Cipla said in a regulatory filing. Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial. Protein-bound paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas. The product is expected to be launched in the first half of the current fiscal year in the US, the Mumbai-based drugmaker said. Shares of the company were trading 2.73 per cent up at Rs 1,454.90 apiece on the BSE.